Previous close | 4.94 |
Open | 5.43 |
Bid | 5.70 x 100 |
Ask | 5.78 x 100 |
Day's range | 5.43 - 6.00 |
52-week range | 4.24 - 11.26 |
Volume | |
Avg. volume | 154,072 |
Market cap | 142.253M |
Beta (5Y monthly) | 1.00 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.04 |
Earnings date | 07 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 14.60 |
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 20,250 shares of its common stock to eleven newly-hired employees, with a grant date of May 6, 2024 (the "Grant Date"). The restricted stock unit
TELA Bio Inc (TELA) released its 8-K filing on May 9, 2024, revealing a significant revenue increase and strategic expansions
MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Reported revenue of $16.6 million in the first quarter, representing growth of 39% over the prior year period of 2023;Delivered the 13th consecutive quarter of at least 35% year-over-year growth;Increased demand fo